These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
218 related items for PubMed ID: 35806472
1. Limited Accuracy of Pan-Trk Immunohistochemistry Screening for NTRK Rearrangements in Follicular-Derived Thyroid Carcinoma. Macerola E, Proietti A, Poma AM, Vignali P, Sparavelli R, Ginori A, Basolo A, Elisei R, Santini F, Basolo F. Int J Mol Sci; 2022 Jul 05; 23(13):. PubMed ID: 35806472 [Abstract] [Full Text] [Related]
3. Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing. Bourhis A, Caumont C, Quintin-Roué I, Magro E, Dissaux G, Remoué A, Le Noac'h P, Douet-Guilbert N, Seizeur R, Tyulyandina A, Schick U, Merlio JP, Marcorelles P, Cappellen D, Uguen A. Pathology; 2022 Feb 05; 54(1):55-62. PubMed ID: 34518039 [Abstract] [Full Text] [Related]
4. A systematic comparison of pan-Trk immunohistochemistry assays among multiple cancer types. Haberecker M, Töpfer A, Melega F, Moch H, Pauli C. Histopathology; 2023 Jun 05; 82(7):1003-1012. PubMed ID: 36759438 [Abstract] [Full Text] [Related]
5. Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions. Brčić I, Godschachner TM, Bergovec M, Igrec J, Till H, Lackner H, Scheipl S, Kashofer K, Brodowicz T, Leithner A, Szkandera J, Liegl-Atzwanger B. Mod Pathol; 2021 Feb 05; 34(2):396-407. PubMed ID: 32860002 [Abstract] [Full Text] [Related]
6. Pan-tumor screening for NTRK gene fusions using pan-TRK immunohistochemistry and RNA NGS fusion panel testing. Koehne de González A, Mansukhani MM, Fernandes H, Hsiao SJ. Cancer Genet; 2022 Apr 05; 262-263():47-52. PubMed ID: 35007853 [Abstract] [Full Text] [Related]
7. Detection of NTRK1/3 Rearrangements in Papillary Thyroid Carcinoma Using Immunohistochemistry, Fluorescent In Situ Hybridization, and Next-Generation Sequencing. Lee YC, Chen JY, Huang CJ, Chen HS, Yang AH, Hang JF. Endocr Pathol; 2020 Dec 05; 31(4):348-358. PubMed ID: 32880785 [Abstract] [Full Text] [Related]
8. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas. Nozaki Y, Yamamoto H, Iwasaki T, Sato M, Jiromaru R, Hongo T, Yasumatsu R, Oda Y. Hum Pathol; 2020 Dec 05; 106():82-92. PubMed ID: 32980422 [Abstract] [Full Text] [Related]
9. Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors. Rudzinski ER, Lockwood CM, Stohr BA, Vargas SO, Sheridan R, Black JO, Rajaram V, Laetsch TW, Davis JL. Am J Surg Pathol; 2018 Jul 05; 42(7):927-935. PubMed ID: 29683818 [Abstract] [Full Text] [Related]
10. Pan-TRK Immunohistochemistry Is Highly Correlated With NTRK3 Gene Rearrangements in Salivary Gland Tumors. Csanyi-Bastien M, Lanic MD, Beaussire L, Ferric S, François A, Meseure D, Jardin F, Wassef M, Ruminy P, Laé M. Am J Surg Pathol; 2021 Nov 01; 45(11):1487-1498. PubMed ID: 33899788 [Abstract] [Full Text] [Related]
11. Screening for NTRK-rearranged Tumors Using Immunohistochemistry: Comparison of 2 Different pan-TRK Clones in Melanoma Samples. Bourhis A, Redoulez G, Quintin-Roué I, Marcorelles P, Uguen A. Appl Immunohistochem Mol Morphol; 2020 Mar 01; 28(3):194-196. PubMed ID: 30920961 [Abstract] [Full Text] [Related]
12. Using pan-TRK and RET Immunohistochemistry for the Detection of Fusion Types of Salivary Gland Secretory Carcinoma. Su YJ, Lee YH, Jin YT, Hsieh MS. Appl Immunohistochem Mol Morphol; 2022 Apr 01; 30(4):264-272. PubMed ID: 35384876 [Abstract] [Full Text] [Related]
13. EPR17341 and A7H6R pan-TRK Immunohistochemistry Result in Highly Different Staining Patterns in a Series of Salivary Gland Tumors. Guibourg B, Cloarec E, Conan-Charlet V, Quintin-Roué I, Grippari JL, Le Flahec G, Marcorelles P, Uguen A. Appl Immunohistochem Mol Morphol; 2020 Oct 01; 28(9):719-724. PubMed ID: 32187023 [Abstract] [Full Text] [Related]
14. The sensitivity of pan-TRK immunohistochemistry in solid tumours: A meta-analysis. Hondelink LM, Schrader AMR, Asri Aghmuni G, Solleveld-Westerink N, Cleton-Jansen AM, van Egmond D, Boot A, Ouahoud S, Khalifa MN, Wai Lam S, Morreau H, Bovee JVMG, van Wezel T, Cohen D. Eur J Cancer; 2022 Sep 01; 173():229-237. PubMed ID: 35933886 [Abstract] [Full Text] [Related]
15. The Pan-TRK Antibody is a Sensitive and Specific Tool for the Detection of NTRK Fusion Genes. Bautista-Wong C, Mojica-González Z, Hop-Garcia K, Bornstein Quevedo L. Appl Immunohistochem Mol Morphol; 2023 Apr 01; 31(4):213-216. PubMed ID: 37017998 [Abstract] [Full Text] [Related]
17. NTRK Fusion in a Cohort of BRAF p. V600E Wild-Type Papillary Thyroid Carcinomas. Lee SE, Lee MS, Bang H, Kim MY, Choi YL, Oh YL. Mod Pathol; 2023 Aug 01; 36(8):100180. PubMed ID: 37003481 [Abstract] [Full Text] [Related]
19. The Diagnostic Value of Pan-Trk Expression to Detect Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion in CNS Tumours: A Study Using Next-Generation Sequencing Platform. Mohamed F, Kurdi M, Baeesa S, Sabbagh AJ, Hakamy S, Maghrabi Y, Alshedokhi M, Dallol A, Halawa TF, Najjar AA, Fdl-Elmula I. Pathol Oncol Res; 2022 Aug 01; 28():1610233. PubMed ID: 35295612 [Abstract] [Full Text] [Related]
20. Pan-tropomyosin receptor kinase immunoreactivity, ETV6-NTRK3 fusion subtypes, and RET rearrangement in salivary secretory carcinoma. Yamamoto H, Nozaki Y, Sugii A, Taguchi K, Hongo T, Jiromaru R, Sato M, Nakano T, Hashimoto K, Fujiwara M, Oda Y. Hum Pathol; 2021 Mar 01; 109():37-44. PubMed ID: 33301751 [Abstract] [Full Text] [Related] Page: [Next] [New Search]